Adult and pediatric patient disposition
| Disposition, n (%) . | Deferasirox cohort . | Crossover cohort . | All patients (n = 555) . | ||
|---|---|---|---|---|---|
| Adults (n = 143) . | Pediatrics (n = 153) . | Adults (n = 139) . | Pediatrics (n = 120) . | ||
| Completed | 74 (51.7) | 107 (69.9) | 88 (63.3) | 102 (85.0) | 371 (66.8) |
| Discontinued | 69 (48.3) | 46 (30.1) | 51 (36.7) | 18 (15.0) | 184 (33.2) |
| Adverse events | 14 (9.8) | 13 (8.5) | 10 (7.2) | 6 (5.0) | 43 (7.7) |
| Abnormal laboratory value | 1 (0.7) | 2 (1.3) | 4 (2.9) | 2 (1.7) | 9 (1.6) |
| Abnormal test procedure result | 1 (0.7) | — | — | — | 1 (0.2) |
| Unsatisfactory therapeutic effect | 11 (7.7) | 4 (2.6) | 7 (5.0) | 4 (3.3) | 26 (4.7) |
| Protocol violation | 1 (0.7) | 1 (0.7) | — | — | 2 (0.4) |
| Withdrawal of consent* | 24 (16.8) | 6 (3.9) | 26 (18.7) | 6 (5.0) | 62 (11.2) |
| Lost to follow-up | — | — | 1 (0.7) | — | 1 (0.2) |
| Administrative problems | 1 (0.7) | — | 1 (0.7) | — | 2 (0.4) |
| Death | 2 (1.4) | 1 (0.7) | 2 (1.4) | — | 5 (0.9) |
| Stopped at end of core | 13 (9.1) | 19 (12.4) | — | — | 32 (5.8) |
| Stopped at end of extension year 3 | 1 (0.7) | — | — | — | 1 (0.2) |
| Disposition, n (%) . | Deferasirox cohort . | Crossover cohort . | All patients (n = 555) . | ||
|---|---|---|---|---|---|
| Adults (n = 143) . | Pediatrics (n = 153) . | Adults (n = 139) . | Pediatrics (n = 120) . | ||
| Completed | 74 (51.7) | 107 (69.9) | 88 (63.3) | 102 (85.0) | 371 (66.8) |
| Discontinued | 69 (48.3) | 46 (30.1) | 51 (36.7) | 18 (15.0) | 184 (33.2) |
| Adverse events | 14 (9.8) | 13 (8.5) | 10 (7.2) | 6 (5.0) | 43 (7.7) |
| Abnormal laboratory value | 1 (0.7) | 2 (1.3) | 4 (2.9) | 2 (1.7) | 9 (1.6) |
| Abnormal test procedure result | 1 (0.7) | — | — | — | 1 (0.2) |
| Unsatisfactory therapeutic effect | 11 (7.7) | 4 (2.6) | 7 (5.0) | 4 (3.3) | 26 (4.7) |
| Protocol violation | 1 (0.7) | 1 (0.7) | — | — | 2 (0.4) |
| Withdrawal of consent* | 24 (16.8) | 6 (3.9) | 26 (18.7) | 6 (5.0) | 62 (11.2) |
| Lost to follow-up | — | — | 1 (0.7) | — | 1 (0.2) |
| Administrative problems | 1 (0.7) | — | 1 (0.7) | — | 2 (0.4) |
| Death | 2 (1.4) | 1 (0.7) | 2 (1.4) | — | 5 (0.9) |
| Stopped at end of core | 13 (9.1) | 19 (12.4) | — | — | 32 (5.8) |
| Stopped at end of extension year 3 | 1 (0.7) | — | — | — | 1 (0.2) |
May include patients who left the study when deferasirox became commercially available.